%0 Journal Article
%T Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial.
%A Mei H
%A Liu X
%A Li Y
%A Zhou H
%A Feng Y
%A Gao G
%A Cheng P
%A Huang R
%A Yang L
%A Hu J
%A Hou M
%A Yao Y
%A Liu L
%A Wang Y
%A Wu D
%A Shen X
%A Jin J
%A Luo J
%A Zeng Y
%A Zhou X
%A Xia R
%A Jiang Z
%A Bai Y
%A Niu T
%A Yang R
%A Hu Y
%J Ann Hematol
%V 103
%N 7
%D 2024 Jul 6
%M 38842566
%F 4.03
%R 10.1007/s00277-024-05826-5
%X While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on the switching from eltrombopag to hetrombopag remains scarce. This post-hoc analysis of a phase III hetrombopag trial aimed to assess the outcomes of ITP patients who switched from eltrombopag to hetrombopag. In the original phase III trial, patients initially randomized to the placebo group were switched to eltrombopag. Those who completed this 14-week eltrombopag were eligible to switch to a 24-week hetrombopag. Treatment response, defined as a platelet count of ≥ 50 × 109/L, and safety were evaluated before and after the switch. Sixty-three patients who completed the 14-week eltrombopag and switched to hetrombopag were included in this post-hoc analysis. Response rates before and after the switch were 66.7% and 88.9%, respectively. Among those with pre-switching platelet counts below 30 × 109/L, eight out of 12 patients (66.7%) responded, while eight out of nine patients (88.9%) with pre-switching platelet counts between 30 × 109/L and 50 × 109/L responded post-switching. Treatment-related adverse events were observed in 50.8% of patients during eltrombopag treatment and 38.1% during hetrombopag treatment. No severe adverse events were noted during hetrombopag treatment. Switching from eltrombopag to hetrombopag in ITP management appears to be effective and well-tolerated. Notably, hetrombopag yielded high response rates, even among patients who had previously shown limited response to eltrombopag. However, these observations need to be confirmed in future trials.